§ Mr. Arnold Shawasked the Secretary of State for Social Services what action she is taking to minimise the risks consequent upon the discovery of faulty ampoules of nupercaine.
§ Dr. OwenThe distribution of nupercaine heavy spinal solution has been stopped pending investigation by the manufacturer into the cause of the defective ampoules. Meanwhile all potential users of this product, which has a specialised use in hospitals and nursing homes, have been warned not to administer the product unless no alternative is available and then only after very careful examination of the ampoules under magnification to ensure that they contain no cracks.
There have been no adverse reports involving patients who have been given nupercaine to date.